Stockreport

Oruka Therapeutics: ORKA-001 For Psoriasis In Focus As 2026 Phase 2 Data Nears [Seeking Alpha]

Oruka Therapeutics, Inc.  (ORKA) 
PDF ORKA-001 could offer significant clinical benefits with only 1 to 2 doses per year. Its Phase 1 suggests a ~100-day half-life. But interestingly, it's possible that h [Read more]